Theranostics 2017; 7(5):1062-1071. doi:10.7150/thno.17908 This issue Cite

Research Paper

Inhibition of platelet function using liposomal nanoparticles blocks tumor metastasis

Yinlong Zhang1,2, Jingyan Wei1✉, Shaoli Liu1,2, Jing Wang2, Xuexiang Han2, Hao Qin2,4, Jiayan Lang2, Keman Cheng2,3, Yiye Li2, Yingqiu Qi2, Greg J Anderson5, Saraswati Sukumar6, Suping Li2✉, Guangjun Nie2,4✉

1. College of Pharmaceutical Science, Jilin University, Changchun 130021, China;
2. CAS Key Laboratory for Biomedical Effects of Nanomaterials & Nanosafety, CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology, Beijing 100190, China;
3. Department of Biomaterials, College of Materials, Xiamen University, Xiamen, 361005, China;
4. University of Chinese Academy of Sciences, Beijing 100049, China.
5. QIMR Berghofer Medical Research Institute, Royal Brisbane Hospital, QLD 4029, Australia.
6. Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD21231, USA.

Citation:
Zhang Y, Wei J, Liu S, Wang J, Han X, Qin H, Lang J, Cheng K, Li Y, Qi Y, Anderson GJ, Sukumar S, Li S, Nie G. Inhibition of platelet function using liposomal nanoparticles blocks tumor metastasis. Theranostics 2017; 7(5):1062-1071. doi:10.7150/thno.17908. https://www.thno.org/v07p1062.htm
Other styles

File import instruction

Abstract

Graphic abstract

Extensive evidence has shown that platelets support tumor metastatic progression by inducing epithelial-mesenchymal transition of cancer cells and by shielding circulating tumor cells from immune-mediated elimination. Therefore, blocking platelet function represents a potential new avenue for therapy focused on eliminating metastasis. Here we show that liposomal nanoparticles bearing the tumor-homing pentapeptide CREKA (Cys-Arg-Glu-Lys-Ala) can deliver a platelet inhibitor, ticagrelor, into tumor tissues to specifically inhibit tumor-associated platelets. The drug-loaded nanoparticles (CREKA-Lipo-T) efficiently blocked the platelet-induced acquisition of an invasive phenotype by tumor cells and inhibited platelet-tumor cell interaction in vitro. Intravenously administered CREKA-Lipo-T effectively targeted tumors within 24 h, and inhibited tumor metastasis without overt side effects. Thus, the CREKA-Lipo formulation provides a simple strategy for the efficient delivery of anti-metastatic drugs and shows considerable promise as a platform for novel cancer therapeutics.

Keywords: Tumor associated platelets, tumor metastasis, liposomal nanoparticle, metastatic inhibition.


Citation styles

APA
Zhang, Y., Wei, J., Liu, S., Wang, J., Han, X., Qin, H., Lang, J., Cheng, K., Li, Y., Qi, Y., Anderson, G.J., Sukumar, S., Li, S., Nie, G. (2017). Inhibition of platelet function using liposomal nanoparticles blocks tumor metastasis. Theranostics, 7(5), 1062-1071. https://doi.org/10.7150/thno.17908.

ACS
Zhang, Y.; Wei, J.; Liu, S.; Wang, J.; Han, X.; Qin, H.; Lang, J.; Cheng, K.; Li, Y.; Qi, Y.; Anderson, G.J.; Sukumar, S.; Li, S.; Nie, G. Inhibition of platelet function using liposomal nanoparticles blocks tumor metastasis. Theranostics 2017, 7 (5), 1062-1071. DOI: 10.7150/thno.17908.

NLM
Zhang Y, Wei J, Liu S, Wang J, Han X, Qin H, Lang J, Cheng K, Li Y, Qi Y, Anderson GJ, Sukumar S, Li S, Nie G. Inhibition of platelet function using liposomal nanoparticles blocks tumor metastasis. Theranostics 2017; 7(5):1062-1071. doi:10.7150/thno.17908. https://www.thno.org/v07p1062.htm

CSE
Zhang Y, Wei J, Liu S, Wang J, Han X, Qin H, Lang J, Cheng K, Li Y, Qi Y, Anderson GJ, Sukumar S, Li S, Nie G. 2017. Inhibition of platelet function using liposomal nanoparticles blocks tumor metastasis. Theranostics. 7(5):1062-1071.

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Popup Image